Chintan Shah, Courtney F Goodman, Alok Sen, Deepak P Edward, Manish Tijare
{"title":"妥布霉素-地塞米松联合滴眼液与人工泪滴眼液治疗病毒性流行性结膜炎的比较:一项随机治疗试验","authors":"Chintan Shah, Courtney F Goodman, Alok Sen, Deepak P Edward, Manish Tijare","doi":"10.1080/02713683.2025.2515997","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To compare the efficacy and safety of one-time povidone-iodine (PovI) administration followed by a course of tobramycin-dexamethasone eye drops versus artificial tears in acute viral conjunctivitis (AVC).</p><p><strong>Methods: </strong>This was a single-centre, randomized controlled trial. Patients with AVC were instilled with PovI (5%) after proparacaine and then divided into two groups using a computer-generated random number table. Group A received combination drops of tobramycin(0.3%) and dexamethasone(0.5%), and group B received carboxymethylcellulose(0.5%) eyedrops. Both groups administered one drop four times daily for at least three days and until complete symptom resolution. A symptom score (SS) encompassing the five symptoms (redness, lid swelling, foreign body sensation, pain, watering; max score 15) was calculated at baseline, day 3, and day 7.</p><p><strong>Results: </strong>The study included 230 eyes (120 in group A, 110 in group B). There was a significant reduction in mean total SS at day 3 (2.16 ± 2.42) and day 7 (0.56 ± 1.14) in all eyes compared to at presentation (8.33 ± 2.46). At day 3, there was a lower mean total SS in group A (1.97 ± 2.31) compared to group B (2.36 ± 2.54) which was marginally significant (<i>p</i> = 0.086). At day 7, the proportion of eyes that were symptom-free was similar between groups (70.9%, <i>p</i> = 0.881). A multivariate analysis found that group B (OR = 2.08, <i>p</i> = 0.036) and a higher pain score (OR = 1.50, <i>p</i> = 0.046) were associated with a lack of clinical resolution by day 3.</p><p><strong>Conclusion: </strong>A course of tobramycin-dexamethasone combination eyedrops after PovI may lead to early symptomatic relief, but recovery was similar to artificial tears by day 7. No significant/sight-threatening complications were observed in any groups.</p>","PeriodicalId":10782,"journal":{"name":"Current Eye Research","volume":" ","pages":"994-1002"},"PeriodicalIF":2.0000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comparison of Tobramycin-Dexamethasone Combination Eyedrop Versus Artificial Tear Eyedrop for the Management of Presumed Viral Epidemic Conjunctivitis: A Randomized Treatment Trial.\",\"authors\":\"Chintan Shah, Courtney F Goodman, Alok Sen, Deepak P Edward, Manish Tijare\",\"doi\":\"10.1080/02713683.2025.2515997\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To compare the efficacy and safety of one-time povidone-iodine (PovI) administration followed by a course of tobramycin-dexamethasone eye drops versus artificial tears in acute viral conjunctivitis (AVC).</p><p><strong>Methods: </strong>This was a single-centre, randomized controlled trial. Patients with AVC were instilled with PovI (5%) after proparacaine and then divided into two groups using a computer-generated random number table. Group A received combination drops of tobramycin(0.3%) and dexamethasone(0.5%), and group B received carboxymethylcellulose(0.5%) eyedrops. Both groups administered one drop four times daily for at least three days and until complete symptom resolution. A symptom score (SS) encompassing the five symptoms (redness, lid swelling, foreign body sensation, pain, watering; max score 15) was calculated at baseline, day 3, and day 7.</p><p><strong>Results: </strong>The study included 230 eyes (120 in group A, 110 in group B). There was a significant reduction in mean total SS at day 3 (2.16 ± 2.42) and day 7 (0.56 ± 1.14) in all eyes compared to at presentation (8.33 ± 2.46). At day 3, there was a lower mean total SS in group A (1.97 ± 2.31) compared to group B (2.36 ± 2.54) which was marginally significant (<i>p</i> = 0.086). At day 7, the proportion of eyes that were symptom-free was similar between groups (70.9%, <i>p</i> = 0.881). A multivariate analysis found that group B (OR = 2.08, <i>p</i> = 0.036) and a higher pain score (OR = 1.50, <i>p</i> = 0.046) were associated with a lack of clinical resolution by day 3.</p><p><strong>Conclusion: </strong>A course of tobramycin-dexamethasone combination eyedrops after PovI may lead to early symptomatic relief, but recovery was similar to artificial tears by day 7. No significant/sight-threatening complications were observed in any groups.</p>\",\"PeriodicalId\":10782,\"journal\":{\"name\":\"Current Eye Research\",\"volume\":\" \",\"pages\":\"994-1002\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Eye Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/02713683.2025.2515997\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/6/22 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Eye Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/02713683.2025.2515997","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/22 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的:比较一次性给药聚维酮碘(PovI)加妥布霉素地塞米松滴眼液与人工泪液治疗急性病毒性结膜炎(AVC)的疗效和安全性。方法:该试验为单中心随机对照试验。AVC患者在服用丙帕卡因后静脉滴注5% PovI,采用计算机生成的随机数字表分为两组。A组给予妥布霉素(0.3%)和地塞米松(0.5%)联合滴眼液,B组给予羧甲基纤维素(0.5%)滴眼液。两组每天四次,每次一滴,持续至少三天,直到症状完全消失。症状评分(SS)包括五种症状(红肿、眼睑肿胀、异物感、疼痛、流泪);在基线、第3天和第7天计算最大评分(15)。结果:共纳入230只眼(A组120只,B组110只)。与首发时(8.33±2.46)相比,全眼平均总SS在第3天(2.16±2.42)天和第7天(0.56±1.14)显著降低。第3天,a组平均总SS(1.97±2.31)低于B组(2.36±2.54),差异有统计学意义(p = 0.086)。第7天,两组无症状眼的比例相似(70.9%,p = 0.881)。多因素分析发现,B组(OR = 2.08, p = 0.036)和较高的疼痛评分(OR = 1.50, p = 0.046)与第3天缺乏临床缓解相关。结论:PovI术后给予妥布霉素-地塞米松联合滴眼液1个疗程可早期缓解症状,但到第7天恢复与人工泪液相似。各组均未见明显/威胁视力的并发症。
Comparison of Tobramycin-Dexamethasone Combination Eyedrop Versus Artificial Tear Eyedrop for the Management of Presumed Viral Epidemic Conjunctivitis: A Randomized Treatment Trial.
Purpose: To compare the efficacy and safety of one-time povidone-iodine (PovI) administration followed by a course of tobramycin-dexamethasone eye drops versus artificial tears in acute viral conjunctivitis (AVC).
Methods: This was a single-centre, randomized controlled trial. Patients with AVC were instilled with PovI (5%) after proparacaine and then divided into two groups using a computer-generated random number table. Group A received combination drops of tobramycin(0.3%) and dexamethasone(0.5%), and group B received carboxymethylcellulose(0.5%) eyedrops. Both groups administered one drop four times daily for at least three days and until complete symptom resolution. A symptom score (SS) encompassing the five symptoms (redness, lid swelling, foreign body sensation, pain, watering; max score 15) was calculated at baseline, day 3, and day 7.
Results: The study included 230 eyes (120 in group A, 110 in group B). There was a significant reduction in mean total SS at day 3 (2.16 ± 2.42) and day 7 (0.56 ± 1.14) in all eyes compared to at presentation (8.33 ± 2.46). At day 3, there was a lower mean total SS in group A (1.97 ± 2.31) compared to group B (2.36 ± 2.54) which was marginally significant (p = 0.086). At day 7, the proportion of eyes that were symptom-free was similar between groups (70.9%, p = 0.881). A multivariate analysis found that group B (OR = 2.08, p = 0.036) and a higher pain score (OR = 1.50, p = 0.046) were associated with a lack of clinical resolution by day 3.
Conclusion: A course of tobramycin-dexamethasone combination eyedrops after PovI may lead to early symptomatic relief, but recovery was similar to artificial tears by day 7. No significant/sight-threatening complications were observed in any groups.
期刊介绍:
The principal aim of Current Eye Research is to provide rapid publication of full papers, short communications and mini-reviews, all high quality. Current Eye Research publishes articles encompassing all the areas of eye research. Subject areas include the following: clinical research, anatomy, physiology, biophysics, biochemistry, pharmacology, developmental biology, microbiology and immunology.